StreetAlpha.app
Home › Stocks › SMMT

Summit Therapeutics Inc. (SMMT)

Healthcare
$9.95
▼ −5.87%
LAST CLOSE · NOV 20

Summit Therapeutics is developing ivonescimab, an investigational cancer antibody being tested in lung and colorectal cancer. It last closed at $9.95 on Nov 20, down 5.87% on the day. The next earnings report for SMMT is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, SMMT reported EPS of -$0.26. Over its last 8 reports the stock moved an average of 10.8% the session after earnings. Over the last 12 months SMMT insiders bought $103.6M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is SMMT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SMMT.

Key Stats

Last 12 months
Results
Net income
−$832.7M
EPS (diluted)
−$1.06
Free cash flow
−$526.9M
Valuation
Market cap
$8.0B
799.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$150.8M
At Sep 30
Shareholder equity
$564.7M
Shares outstanding
799.8M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$88.6M−$88.6MFY2021FY2022: −$78.8M−$78.8MFY2022FY2023: −$614.9M−$614.9MFY2023FY2024: −$221.3M−$221.3MFY2024FY2025: −$1.1B−$1.1BFY2025

From SMMT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.26
Quarter ended Sep 2026
Year ago EPS
-$0.31
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.09Dec '24Mar 2025: -$0.09Mar '25Jun 2025: -$0.76Jun '25Sep 2025: -$0.31Sep '25Dec 2025: -$0.28Dec '25Mar 2026: -$0.24Mar '26Jun 2026: -$0.28Jun '26Sep 2026: -$0.26Sep '26Latest -$0.26
Revenue by quarter
Not enough quarters on file yet.
How SMMT moved after its last 8 reports
Average move the session after a report ±10.8%
Nov 4, 2026After the close−12.2%
Jul 23, 2026After the close−8.8%
Apr 30, 2026After the close−24.9%
Feb 23, 2026After the close+0.2%
Jan 12, 2026Time not announced−13.4%
Oct 20, 2025Time not announced−4.5%
Aug 11, 2025After the close−9.1%
May 1, 2025After the close+13.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SMMTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on SMMT: 0 upgrades, 0 downgrades, 0 initiations
CitigroupTarget cut
Nov 16  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on SMMT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SMMT

Technical Analysis

SMMT · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 46% below its 20 day and 58% below its 50 day average. It is 61% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $9.89, and the nearest resistance the Pivot at $10.15.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.5%/day
Key levels
$29.2352 week high+193.8%
$16.06200 day average+61.4%
$15.7450 day average+58.2%
$15.10100 day average+51.8%
$14.81Swing high (Jun 23)+48.8%
$14.5120 day average+45.8%
$10.41Pivot R1+4.6%
$10.15Pivot+2.0%
$9.95Last close
$9.8952 week low−0.6%
$9.69Pivot S1−2.6%
Indicators
RSI (14)30.28Weak, oversold below 30Neutral
MACD-1.37Below its signal lineBearish
Stochastic3.5Near the bottom of its rangeOversold
ADX (14)25.5Trending down
Williams %R-99.3Oversold below −80, overbought above −20Oversold
CCI (20)-160.9Oversold below −100, overbought above 100Oversold
Rate of change−39.1%Change over 10 sessionsBearish
ATR (14)$1.24Typical daily range, 12.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SMMT

What happened before

See how SMMT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SMMT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SMMT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SMMTHow many large options trades hit SMMT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SMMT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲199 buying vs 106 selling
  • ●Held by funds -0.2 pts
  • ▲Funds holding +52
  • ▼Superinvestors: 1 added, 2 cut
  • ▼Put/call 0.67 to 0.92
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding298246+21.1%
In funds' top 10110.0%
Held by funds16.9%17.0%−0.2 pts
New / increased91 / 10857 / 98+28.4%
Reduced / sold out66 / 4057 / 36+14.0%
Put/call ratio0.920.67+37.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SMMT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SMMT Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$103.6M5 buys · 3 insiders
Sold$00 sales · 0 insiders
Cluster buy: 3 insiders bought $103.6M between Jun 4 and Jun 12.
2026-06 bought $103.6MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 12Robert W DugganCo-CEOBuy3,810,000$13.12$50.0M
Jun 12Mahkam ZanganehCo-CEOBuy3,810,000$13.12$50.0M
Jun 4Robert W DugganCo-CEOBuy100,000$14.60$1.5M
Jun 4Mahkam ZanganehCo-CEOBuy100,000$14.60$1.5M
Jun 4Manmeet Singh SoniCOO and CFOBuy50,000$14.45$722K
Oct 21, 2025Robert W DugganCo-CEOBuy26,680$18.74$500K
Every insider buy and sale for SMMT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SMMT insider trades →

From SEC Form 4 filings by SMMT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SMMT is in one of them and how their past SMMT trades turned out.

SMMT in the AI portfolios
Loading…

SMMT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SMMT in an article yet. Here's the latest on the wider market.

SMMT in the news

About Summit Therapeutics

Summit Therapeutics is a biopharmaceutical company based in Miami, Florida, that develops cancer medicines. Its lead candidate, ivonescimab, is an investigational antibody designed to act on two proteins, one that helps tumors evade the immune system and one that supports blood vessel growth in tumors. The company is testing ivonescimab in lung cancer and colorectal cancer, and it holds development and commercial rights in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. Its intended users are cancer patients and the physicians who treat them.

Headquarters
Miami, FL